公开(公告)号：US20180303869A1

公开(公告)日：2018-10-25

申请号：US15823996

申请日：2017-11-28

申请人： Clarus CLS Holdings, LLC

发明人： C. Michael SAMSON ,  Bo LIANG ,  Joseph A. CAPRIOTTI

IPC分类号： A61K31/79 ,  A61K47/38 ,  A61K9/00 ,  A61K47/34 ,  A61K47/02 ,  A61K31/24 ,  A61K33/18 ,  A61K31/80 ,  A61K31/407 ,  A61K31/245 ,  A61K47/18 ,  A61K31/192 ,  A61K31/196 ,  A61K31/4535 ,  A61K31/56 ,  A61K31/573 ,  A61K45/06

CPC分类号： A61K31/79 ,  A61K9/0048 ,  A61K31/192 ,  A61K31/196 ,  A61K31/24 ,  A61K31/245 ,  A61K31/407 ,  A61K31/4535 ,  A61K31/56 ,  A61K31/573 ,  A61K31/80 ,  A61K33/18 ,  A61K45/06 ,  A61K47/02 ,  A61K47/183 ,  A61K47/34 ,  A61K47/38 ,  A61K2300/00

摘要： A topical ophthalmic composition comprised of povidone-iodine 0.01% to 10.0% combined with a steroid or non-steroidal anti-inflammatory drug. This solution is useful in the treatment of active infections of at least one tissue of the eye (e.g., conjunctiva and cornea) from bacterial, mycobacterial, viral, fungal, or amoebic causes, as well as treatment to prevent such infections in appropriate clinical settings (e.g. corneal abrasion, postoperative prophylaxis, post-LASIK/LASEK prophylaxis). Additionally the solution is effective in the prevention of infection and inflammation in the post-operative ophthalmic patient.

公开(公告)号：US10849928B2

公开(公告)日：2020-12-01

申请号：US15823996

申请日：2017-11-28

申请人： Clarus CLS Holdings, LLC

发明人： C. Michael Samson ,  Bo Liang ,  Joseph A. Capriotti

IPC分类号： A61K31/79 ,  A61K9/00 ,  A61K31/192 ,  A61K31/196 ,  A61K31/4535 ,  A61K31/56 ,  A61K31/573 ,  A61K45/06 ,  A61K31/245 ,  A61K31/407 ,  A61K31/80 ,  A61K33/18 ,  A61K31/24 ,  A61K47/02 ,  A61K47/34 ,  A61K47/38

摘要： A topical ophthalmic composition comprised of povidone-iodine 0.01% to 10.0% combined with a steroid or non-steroidal anti-inflammatory drug. This solution is useful in the treatment of active infections of at least one tissue of the eye (e.g., conjunctiva and cornea) from bacterial, mycobacterial, viral, fungal, or amoebic causes, as well as treatment to prevent such infections in appropriate clinical settings (e.g. corneal abrasion, postoperative prophylaxis, post-LASIK/LASEK prophylaxis). Additionally the solution is effective in the prevention of infection and inflammation in the post-operative ophthalmic patient.